Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tci GeneROCO:6879 65 PS Ratio is 3.40 as of Jul. 22, 2026, which is 35% below its 10-year median of 5.24. GuruFocus rates ROCO:6879 with a GF Score™ of 65/100 and a GF Value™ of NT$48.81 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 930 Biotechnology companies, Tci Gene ranks better than 75.05% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Tci Gene's share price is NT$35.00.
Tci Gene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$10.28. Hence, Tci Gene's PS Ratio for today is 3.40.
Warning Sign:
Tci Gene Inc stock PS Ratio (=3.39) is close to 1-year high of 3.72.
The historical rank and industry rank for Tci Gene's PS Ratio or its related term are showing as below:
ROCO:6879'
s PS Ratio Range Over the Past 10 Years
Min: 2.73 Med: 5.24 Max: 7.74
Current: 3.4
During the past 7 years, Tci Gene's highest PS Ratio was 7.74. The lowest was 2.73. And the median was 5.24.
ROCO:6879's PS Ratio is ranked better than 75.05% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs ROCO:6879: 3.40
Tci Gene's Revenue per Sharefor the
six
months ended in Dec. 2025 was NT$4.94.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$10.28.
Warning Sign:
Tci Gene Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Tci Gene was -21.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -5.20% per year.
During the past 7 years, Tci Gene's highest 3-Year average Revenue per Share Growth Rate was 19.90% per year. The lowest was -15.80% per year. And the median was -4.40% per year.
Back to Basics: PS Ratio
Tci Gene (ROCO:6879) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Tci Gene PS Ratio Related Terms
Tci Gene PS Ratio Historical Data
* Premium members only.
The historical data trend for Tci Gene's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6879 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Tci Gene's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tci Gene PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tci Gene's PS Ratio distribution charts can be found below:
* The bar in red indicates where Tci Gene's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Tci Gene's Share Price of today is NT$35.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tci Gene's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$10.28.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Tci Gene (ROCO:6879) has a PS Ratio of 3.40 as of Jul. 22, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tci Gene and its competitors. This is 35% below median its historical median of 5.24. Over the past decade, Tci Gene's PS Ratio has ranged from 2.73 to 7.74. According to the industry distribution chart, Tci Gene ranks #232 out of 930 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Tci Gene's PS Ratio too high?
Tci Gene's current PS Ratio of 3.40 is 35% below median its 10-year median of 5.24. Over the past 10 years, this metric has ranged from a low of 2.73 to a high of 7.74. The Biotechnology industry median PS Ratio is 9.30. Tci Gene's value of 3.40 is 63.4% below this industry median. Based on the distribution chart, Tci Gene ranks #232 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Tci Gene has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tci Gene's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tci Gene ranks #232 out of 930 companies for PS Ratio. This places Tci Gene in the top 25% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.30. Tci Gene's value of 3.40 is 63.4% below this benchmark. Historically, Tci Gene's own PS Ratio has ranged from 2.73 to 7.74 over the past decade. While the company's 10-year median is 5.24 vs. the industry median of 9.30, Tci Gene has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tci Gene's current PS Ratio of 3.40 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tci Gene and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tci Gene's current PS Ratio is 3.40, which is 35% below median its own 10-year median of 5.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tci Gene stock overvalued right now?
Based on GuruFocus' analysis, Tci Gene (ROCO:6879) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$48.81, compared to a current price of NT$35.00 — trading 28.3% below its estimated fair value. The current PS Ratio is 3.40, which is 35% below median its 10-year median of 5.24 and 63.4% below the Biotechnology industry median of 9.30. Tci Gene's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Tci Gene (ROCO:6879), the current PS Ratio is 3.40 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tci Gene (ROCO:6879) Overvalued in 2026?
Based on GuruFocus' analysis, Tci Gene stock appears to be undervalued.
The current stock price of NT$35.00 is trading 28.3% below its estimated GF Value™ of NT$48.81.
GuruFocus considers Tci Gene to be Modestly Undervalued.
Key valuation signals for ROCO:6879:
PS Ratio: 3.40 (35% below median its 10-year median of 5.24)
GF Value™: NT$48.81 vs. price of NT$35.00 (28.3% below fair value)
Industry Position: 63.4% below the Biotechnology median (#232 of 930)
No single metric tells the full story. See the ROCO:6879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.
65GF Score
Get the complete analysis for ROCO:6879
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6879 has been successfully added to your 
